Incyte (INCY) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed Incyte (INCY) over the past year, gaining 166.3% versus a gain of 32.1%. Over five years, INCY leads with a +72.0% price change compared with -53.3% for OABI. Incyte is the larger company by market cap ($22.82 billion vs $691.3 million), about 33.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCY | OABI |
|---|---|---|
| Share price | $112.57 | $4.76 |
| Market cap | $22.82B | $691.33M |
| 1-day change | -0.16% | +2.04% |
| YTD return | +14.15% | +151.89% |
| 1-year return | +32.06% | +166.29% |
| 5-year return | +71.98% | -53.26% |
| P/E ratio (TTM) | 14.34 | — |
| Forward P/E | 12.87 | — |
| EPS (TTM) | $7.85 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.14B | — |
| Revenue growth (YoY) | +21.22% | — |
| Net income (latest FY) | $1.29B | — |
| Gross margin | 92.76% | — |
| Operating margin | 29.46% | — |
| Net margin | 25.03% | — |
| 52-week high | $132.60 | $5.43 |
| 52-week low | $82.82 | $1.30 |
| Distance from 52-week high | -15.11% | -12.43% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +14.71% | +75.18% |
| Average volume | 1.63M | 1.47M |
| Shares outstanding | 202.70M | 145.39M |
| Employees | 2,844 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Incyte is about 33.0 times larger than OmniAb by market value ($22.82B vs $691.33M).
- OABI has outperformed INCY by 134.2 percentage points over the past year.
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
INCY vs OABI FAQ
Which is bigger, Incyte or OmniAb?
Incyte (INCY) is larger, with a market capitalization of $22.82B compared with $691.33M for OmniAb (OABI).
Which stock has performed better over the past year, INCY or OABI?
OABI returned +166.29% over the past 12 months, compared with +32.06% for INCY (price return, excluding dividends). Past performance does not predict future results.
Are Incyte and OmniAb in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.